Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

Technology appraisal guidance
Reference number: TA263
Published: 22 August 2012

TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: appendix B - GE proposal paper - June 2015

TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: appendix B - GE proposal paper - June 2015

TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: appendix B - GE proposal paper - June 2015
29 June 2015
(223.97 Kb 5 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 25 June 2015